Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
Portfolio Pulse from
Bausch Health's XIFAXAN® (rifaximin) has been selected for the Medicare Negotiation Program under the Inflation Reduction Act, with price applicability starting in 2027. The company plans to engage with CMS to discuss the drug's value and recommendations from liver disease associations.
January 17, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bausch Health's XIFAXAN® has been chosen for Medicare price negotiations, potentially impacting future pricing and revenue. The company will engage with CMS to discuss the drug's value.
The selection of XIFAXAN® for Medicare price negotiations could affect Bausch Health's future pricing strategy and revenue from this drug. However, the impact is not immediate as the price applicability starts in 2027. The company's proactive engagement with CMS and the high recommendations from liver disease associations may mitigate potential negative impacts.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90